GOG-0239
Terminated
Protocol Information
Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants
A Phase II Trial of AZD6244 (NSC# 748727, IND# 77782) in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Principal Investigator
John H Farley
Status
Terminated
Closed to Accrual
November 23, 2009
Closed to Accrual & Treatment
October 15, 2020
Complete
October 15, 2020
Terminated
November 13, 2020
Disease Site
Gynecologic [GY] Ovarian
Phase
II
Developmental Therapeutics
No
Primary Objective
To examine the tumor response rate of patients on AZD6244 (NSC #748727).
To examine the acute toxicity of AZD6244 (NSC #748727) during the first course of treatment using CTCAE version 3.0.
To define the pharmacokinetic profile for AZD6244, 100 mg administered orally twice daily.
Patient Population
Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum.
Target Accrual
51
Protocol Document
Informed Consent
Tracked Amendments
Previous Protocol Versions
Study Memos
Safety Reports
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.
-
Share this study.
-
-
-
-
